demonstrated that treating human lung cancer cell line H1299 with the APJ antagonist ML221 resulted in a reduction in the levels of migratory markers such as Vimentin, MMP‐9 and MMP‐3, subsequently inhibiting tumour invasion. Here, MMP9 is linked to lung cancer.